



**National
Multiple Sclerosis
Society**

Patient Perspectives

Tim Coetzee

Disclosures

T. Coetzee is an employee of the National Multiple Sclerosis Society. The Society is supported by individuals, foundations and corporations, including pharmaceutical companies. Less than 5% of the Society's annual revenue comes from pharmaceutical companies with a marketed MS treatment.

**Point 1 - Patient perspectives
and attitudes to clinical trials are
evolving and continue to evolve**



From passengers to co-pilots: Patient roles expand

Margaret Anderson and K. Kimberly McCleary Sci. Transl. Med. (2015)



Addressing a patient's part
in advancing biomedicine

**SCLE
ROSI
MULT
IPLA**
associazione
italiana

un mondo
libero dalla SM

***1947 – Nuremburg Code adoption of the
informed consent***




***....1984 – the HIV/AIDS movement
catapulted patient needs to the forefront of
research and created the force for change
that dramatically altered regulatory
approval processes at the U.S. Food and
Drug Administration (FDA), funding
formulas and emphasis at the U.S. National
Institutes of Health (NIH), and the path
forward for disease advocacy
organizations.....***

Provided by P. Zaratin, Italian MS Society





Point 2 – We need to shift from a recruitment mindset to an engagement mindset





MULTI-ACT and Science of Patient Input A Collective Research Impact Framework and multi-variate models to foster the true engagement of actors and stakeholders in Health Research and Innovation



Paola Zaratin, MULTI-ACT project coordinator on behalf of MULTI-ACT Consortium

Multi-Act
This project has received funding from the European
Union's Horizon 2020 Research and Innovation Programme
under the Grant Agreement No. 787570



Point 3 – It's still about developing safe, effective treatments and ensuring affordable access matters as well.

